NLRP3 and age: Our findings suggest that inhibition of NLRP3 inflammasome components could serve as such a comprehensive novel therapeutic approach that can inhibit the downstream effects of VEGF‐A that promote age‐related pathologies, without causing the adverse side effects of anti‐VEGF‐A therapies and without impairing tissue vascularization.